Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.
Background: Precise staging of esophageal cancer (EC) is important for selection of optimal treatment option
and prognostication. Aim of this study was to assess the role of 18FDG PET/CT in staging and response evaluation
to neoadjuvant chemoradiation (nCR) in EC patients using standardized imaging protocol. Material and methods:
This prospective study was conducted at PET/CT Section of Department of Radiology, Aga Khan University Hospital
Karachi, Pakistan from July 2017 till February 2018. We included 34 biopsy proven EC patients who had 18FDG
PET/CT and CT of neck, chest and abdomen as part of initial staging. Eleven patients had post-nCR 18FDG PET/CT
using standardized imaging protocol as per EANM guidelines. CT and PET/CT based staging was compared. Based
on PERCIST criteria, response evaluation was assessed using change in highest SUVmax (%ΔSUVmax) in baseline
and follow-up scans (primary lesion, node or extra-nodal metastases). Results: Mean age of cohort was 57 ± 14 years
(23 males and 11 females) having adenocarcinoma (AC) in 23 and squamous cell cancer (SCC) in 11 patients. Mean
18FDG dose, uptake time and hepatic SUVmean for baseline scans were 169 ±54 MBq, 65 ±10 minute and 1.91 ± 0.49
which were within ± 10%, ± 15% and ± 20% for follow-up scans in 11 patients respectively. Mean size (craniocaudal
dimension in mm) and SUVmax of primary tumor was 56 ±27 mm and 13.4 ± 4.7. Based on 18FDG PET/CT findings,
patients were categorized into N0 (10/34), N1 (09/34), N2 (11/34) and N3 (04/34) while 11/32 had stage IV disease.
No significant difference was seen in AC and SCC groups. CT found stage IV disease in 3/34 (09%) while PET/CT
found in 11/34 (32%; p value: 0.019) cases. PET/CT showed concordance with CT in 41% while discordance (all
with upstaging) seen in 59%. On follow-up PET/CT, complete metabolic response was seen in 5/11 (45%) and partial
metabolic response was noted in 6/11 (55% - p value non-significant) patients. Median %ΔSUVmax over primary
lesions was 49.84% (-32.69 -100%) while over nodal sites it was 41.18% (-82.60 -100%). Conclusion: We conclude
that 18FDG PET/CT was found a sensitive tool in initial staging of EC. Compared with CT, it had higher diagnostic
accuracy for distant nodal and extra-nodal metastasis. %ΔSUVmax between baseline and post-nCR studies acquired
with standardized protocol had changed management in more than half of our patients. For response evaluation in EC
more studies with standardized 18FDG PET/CT imaging protocols are warranted.
['Fatima|Nosheen|N|', 'Zaman|Maseeh Uz|MU|', 'Zaman|Areeba|A|', 'Zaman|Unaiza|U|', 'Tahseen|Rabia|R|', 'Zaman|Sidra|S|']
D000230:Adenocarcinoma D000328:Adult D000368:Aged D000369:Aged, 80 and over D002294:Carcinoma, Squamous Cell D059186:Chemoradiotherapy, Adjuvant D004938:Esophageal Neoplasms D005260:Female D019788:Fluorodeoxyglucose F18 D005500:Follow-Up Studies D006801:Humans D008297:Male D008875:Middle Aged D020360:Neoadjuvant Therapy D009367:Neoplasm Staging D000072078:Positron Emission Tomography Computed Tomography D011446:Prospective Studies D019275:Radiopharmaceuticals
Esophageal Cancer standardized protocol 18FDG PET/CT and CT staging and response evaluation, neoadjuvant chemoradiation